CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 829 enrolled
Drug / intervention
Non-Interventionalother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04336215
NCT04336215N/ACompleted

Cohort Study of SARS-CoV-2 Incidence, Transmission, and Disease Severity in Healthcare Workers

Rutgers, The State University of New Jersey·observational·Posted Apr 7, 2020·Updated May 15, 2026

In Brief

An observational study evaluating Non-Interventional for Coronavirus and SARS-CoV-2. Completed, enrolled 829 participants across 7 sites.

Detailed Summary

Our long-term goal is to protect the health care workforce (HCW) caring for SARS-CoV-2-infected patients, their families, communities, and the general population. Our specific objective is to rapidly establish a prospective cohort to characterize the factors related to viral transmission and disease severity in a large healthcare system. We addressed this hypothesis by recruiting and longitudinally following 546 HCW and a comparison group of 283 non-HCW within a large academic health system, Rutgers Biomedical and Health Sciences (RBHS). By intensively following participants over a several year period (2020-2024) and collecting serial biospecimens (nasopharyngeal/throat swabs, blood, and saliva) and questionnaire data at multiple time points, we will uniquely characterize SARS-CoV-2 transmission and risk factors for COVID-19 among HCW and our larger academic community.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedApr 7, 2020
Enrollment StartApr 7, 2020
Primary CompletionAug 31, 2024
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 6.2 years ago

Interventions

Non-Interventionalother

This non-interventional study poses no additional risks to people with pre-existing conditions.